Clinical characteristics and risk factors analysis of lung metastasis from benign giant cell tumor of bone

Yang, Yanzhi; Huang, Zhen; Niu, Xiaohui; Xu, Hairong; Li, Yuan; Liu, Weifeng

doi:10.1016/j.jbo.2017.04.001

Cited by 36 publications

(59 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Based on the Campanacci classi cation, which has been widely accepted for evaluating giant cell tumours, grade III tumours are the aggressive type. A series of studies reported Campanacci grade III as a risk factor for tumour recurrence [20,21] and lung metastasis [22,23]. Recurrence was also reported to be a risk factor for metastasis [22,23].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Survival and Prognostic Factors Analyses in Malignant Giant Cell Tumor of Bone

Zhang¹,

Wang²,

Lin³

et al. 2020

Preprint

View full text Add to dashboard Cite

Background: The characteristics and survival of patients with malignant giant cell tumour of bone (GCTB) have not been investigated thoroughly due to the rarity of the disease. We evaluated these factors in a large cohort in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database.Methods: Data from patients who were diagnosed with malignant GCTB from 1975 to 2016 were extracted from the SEER database. The overall survival was calculated by Kaplan–Meier analysis, and intergroup differences were tested by the log-rank test. Univariate and multivariate Cox proportional hazard regression analyses were conducted to identify the independent survival factors.Results: A total of 325 patients with malignant GCTB were included. The overall 1-, 5-, and 10-year survival rates were 94.3% (95% CI: 91.7-96.8), 82.3% (95% CI: 77.9-86.6), and 80.1% (95% CI: 75.4-84.7), respectively. A potential non-linear J-shaped dose–response relationship between the age or diagnosis year and survival were found. Multivariate Cox regression showed poor survival in patients with age from 35 to 60 years (HR=9.99, 95% CI: 1.34-74.80, P=0.025), age older than 60 years (HR=62.03, 95% CI: 7.94-484.38, P<0.001), with stage T2 disease (HR=4.85, 95% CI: 1.52-15.47, P=0.008), with stage T3 disease (HR=6.09, 95% CI: 1.03-36.23, P=0.047), and with distant tumours (HR=2.76, 95% CI: 1.14-6.65, P=0.024), and extraskeletal sites (HR=3.33, 95% CI: 1.02-10.85, P=0.046).Conclusions: This large population-based series described the clinical characteristics of malignant GCTB. Patients with stage T2/3 disease, distant disease and extra-skeletal sites had more odds to be with worse survival. The elder age than 34 years had a gradually increased risk for survival.

show abstract

Section: Discussionmentioning

confidence: 99%

“…A series of studies reported Campanacci grade III as a risk factor for tumour recurrence [20,21] and lung metastasis [22,23]. Recurrence was also reported to be a risk factor for metastasis [22,23]. Therefore, T stage and/or Campanacci classi cation played an important role in evaluating the survival of patients with giant cell tumours.…”

Section: Discussionmentioning

confidence: 99%

Survival and Prognostic Factors Analyses in Malignant Giant Cell Tumor of Bone

Zhang¹,

Wang²,

Lin³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Based on the Campanacci classification, which has been widely accepted in evaluating giant cell tumor, grade III represented the aggressive type. A series of studies reported Campanacci grade III as the risk factor for tumor recurrence [19,20] and lung metastasis [21,22]. The recurrence was also reported to be a risk factor for resulting in metastasis [21,22].…”

Section: Discussionmentioning

confidence: 99%

Survival and prognostic factors analyses in malignant giant cell tumor of bone

Zhang¹,

Wang

Li³

et al. 2019

Preprint

View full text Add to dashboard Cite

Background The characteristics and survival in patients with malignant giant tumor cancer of bone (GCTB) were not investigated thoroughly due to the limited population. We evaluated the issues based on a large cohort in the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) database. Methods Patients who were diagnosed with malignant GCTB from 1975 to 2016 were extracted from the SEER database. The overall survival (OS) was calculated by Kaplan–Meier analysis and the inter-group difference was tested by log-rank test. Univariate and multivariate Cox proportional hazard regression were conducted to identify the independent survival factors. Results A total of 325 patients with malignant GCTB were included. The overall 1-, 5-, and 10-year survival rates were 94.3% (95% CI: 91.7-96.8), 82.3% (95% CI: 77.9-86.6), and 80.1% (95% CI: 75.4-84.7), respectively. In the univariate analysis, age older than 34 years, grade IV, T2/3 stage, M1, distant and surgery of the primary site. Multivariate Cox regression showed the poor survival in patients with age older than 34 years (hazard ratio (HR) =3.68, 95% CI: 2.06-6.57, P<0.001), T2 stage (HR=4.96, 95% CI: 1.57-15.63, P=0.006), distant tumor (HR=3.02, 95% CI: 1.32-6.92, P=0.009), and the extra-skeletal sites (HR=8.84, 95% CI: 2.89-27.07, P<0.001), respectively. Conclusions This large population-based series described the clinical characteristics of the malignant GCTB. Age, T2, distant tumor and extra-skeletal sites were determinant survival factors of the patients with malignant GCTB.

show abstract

“…2A). Although classified as a benign tumor, GCTB can be associated with potentially aggressive behavior and a 1-9% incidence of lung metastasis [9]. A Transwell assay indicated that rhCCL20 dramatically promoted GCTSC migration (Fig.…”

Section: Ccl20 Promotes Gctsc Proliferation and Migration In An Autocmentioning

confidence: 98%

“…GCTB is classified as a benign but local aggressive tumor with a 1-9% incidence of lung metastasis [9]. Currently, the most effective treatment for GCTB is surgical excision.…”

Section: Introductionmentioning

confidence: 99%

Stromal Cell-Derived CCL20 Promotes Tumor Progression and Osteolysis in Giant Cell Tumor of Bone

Zhao

Wang

Tang

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Giant cell tumor of bone (GCTB), one of the most common primary bone tumors, leads to extensive bone destruction. However, the mechanisms underlying GCTB progression remain elusive and prognostic factors and treatment targets are required. In the current study, we explored the function of the chemokine family member CCL20 in GCTB progression. Methods: We explored the expression of CCL20 in stromal cells (GCTSCs) using microarray. Clinical analyses of the role of CCL20 in tumor progression were performed based on the patient cohort of our institution. The role of CCL20 in tumor proliferation was evaluated by MTS assay, migration ability was measured by a Transwell assay, and osteoclastogenesis was induced by CCL20 or GCTSC-conditioned medium. Quantitative PCR and western blot were used to measure the expression levels of mRNAs and proteins related to tumor progression. Results: CCL20 was upregulated in GCTSCs and correlated with tumor progression and prognosis. CCL20 induced GCTSC proliferation and migration in an autocrine manner. In addition, CCL20 recruited mononuclear cells and induced osteoclastogenesis by overactivating the AKT and NF-κB signaling pathways. Antibody blockade of CCL20 abolished the exacerbated osteoclastogenesis. Conclusion: Taken together, our data indicate that GCTSC secretion of CCL20 acts as a key modulator in the pathological progression of GCTB. It can promote GCTSC proliferation and migration in an autocrine manner and can recruit bone marrow monocytes to the tumor microenvironment and enhance osteoclastogenesis in a paracrine manner. These findings strongly indicate the potential prognostic and therapeutic value of CCL20 in GCTB.

show abstract

Clinical characteristics and risk factors analysis of lung metastasis from benign giant cell tumor of bone

Cited by 36 publications

References 21 publications

Survival and Prognostic Factors Analyses in Malignant Giant Cell Tumor of Bone

Survival and Prognostic Factors Analyses in Malignant Giant Cell Tumor of Bone

Survival and prognostic factors analyses in malignant giant cell tumor of bone

Stromal Cell-Derived CCL20 Promotes Tumor Progression and Osteolysis in Giant Cell Tumor of Bone

Contact Info

Product

Resources

About